Document is current

Article History

Received: 17 August 2023

Revised: 12 April 2024

Accepted: 17 April 2024

First Online: 7 May 2024

Competing interests

: MO has consulting/advisory arrangements with Merck, MSD and Transgene. Research support from Merck and Roche. The institution receives clinical trial support from Abbvie, Ayala Pharmaceutical, MSD, ALX Oncology, Debiopharm International, Merck, ISA Pharmaceuticals, Roche Pharmaceuticals, Boehringer Ingelheim, Seagen, Gilead. Travel accommodations expenses: BMS, MSD, Merck. AS has consulting/advisory arrangements with Merck, Bristol-Myers Squibb, Novartis, Oncorus, Janssen, Medison & Immunocore. The institution receives clinical trial support from: Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma/Pfizer, GSK, Treadwell, ALX Oncology, Amgen, Servier. RMN has consulting/advisory arrangements with Merck, Bristol-Myers Squibb, Roche, Seattle Genetics, Astra Zeneca, Pfizer, Boehringer Ingelheim. Speaker Bureau honoraria from Merck, MSD and Boehringer Ingelheim. GW has consulting/advisory arrangements with Gilead, Novartis, Pfizer, AstraZeneca, Boehringer-Ingelheim. Research support from Pfizer. Travel grants from BMS, Abbvie.

: ROMA LA-OPSCC-002 was a prospective interventional trial that involved MET-4 drug administration and the collection and analysis of oropharyngeal swabs, stool and plasma samples. The study did not determine the eligibility to receive standard-of-care treatment with definitive chemoradiotherapy. The study was approved by the Princess Margaret Cancer Center Institutional Research Ethics Board (Study ID 19-5079.10) and was conducted in accordance with the Declaration of Helsinki. All patients provided written, signed, informed consent to participate.